Rini BI, et al. - Through a multicenter, open-label, phase 3, randomized controlled trial with 152 academic medical centers recruiting 915 patients, researchers report results of IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in first-line metastatic renal cell carcinoma. Prolongation of progression-free survival was seen with atezolizumab plus bevacizumab vs sunitinib in patients with metastatic renal cell carcinoma along with a favorable safety profile. For the establishment of a survival benefit, longer-term follow-up is necessary. For selected patients with advanced renal cell carcinoma atezolizumab plus bevacizumab is a good option for first-line treatment option. Median progression-free survival was 11.2 months with atezolizumab plus bevacizumab vs 7.7 months with sunitinib in the PD-L1 positive population.